Debut Plus

₹330.4

▲ +0.26 +0.08%

As of 10 Sept 2026 · delayed

NSE Listed

Marksans Pharma Limited (MARKSANS)

Volume: 12,95,256Avg Vol 1W: 25,24,533.8Avg Vol 1M: 38,93,666.252W Range:₹155₹349.95
NSE BSE www.marksanspharma.com AI Report
Key Ratios
Checked 5h ago
Market Cap₹14,973 Cr
Current Price₹330.4
Previous Close₹330.14
High / Low (52w)₹349.95 / ₹155
Volume12,95,256
Avg Vol (1W)25,24,533.8
Avg Vol (1M)38,93,666.2
Stock P/E28.98
Book Value₹66.71
Dividend Yield27%
ROE13.82%
ROA13.5%
Revenue (TTM)₹3,033 Cr
Revenue Growth20.5%
Profit Margin16.29%
Total Debt₹0 Cr
Shares Outstanding45 Cr
Face Value₹1
EPS (TTM)₹11.4
P/B4.95
Debt / Equity0.12
50 DMA₹291.79
200 DMA₹220.29
Day change+0.08%
Price Chart
₹330.4▲ 86.77% · 1Y
₹336₹1574.8Cr
2025-09-10
2026-09-10

20-day avg volume: 38.9L shares

Pros
  • Pays a dividend yield of 27.0%.
  • Company is almost debt-free.
Cons
  • Revenue fell 11% YoY.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹642 Cr₹682 Cr₹708 Cr₹620 Cr₹720 Cr₹754 Cr₹856 Cr₹841 Cr
EBITDA₹127 Cr₹146 Cr₹120 Cr₹83 Cr₹139 Cr₹157 Cr₹206 Cr₹214 Cr
Net Profit₹97 Cr₹105 Cr₹91 Cr₹58 Cr₹98 Cr₹113 Cr₹148 Cr₹157 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹2,689 Cr₹299 Cr₹320 Cr₹320 Cr₹340 Cr₹362 Cr₹3,033 Cr₹321 Cr
EBITDA₹516 Cr₹50 Cr₹64 Cr₹122 Cr₹82 Cr₹125 Cr₹585 Cr₹91 Cr
Net Profit₹381 Cr₹38 Cr₹48 Cr₹100 Cr₹61 Cr₹92 Cr₹418 Cr₹69 Cr
EPS8.4—————9.22—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹804 Cr₹903 Cr₹1,229 Cr₹1,640 Cr₹2,190 Cr₹2,681 Cr₹3,240 Cr₹3,861 Cr
Total Liabilities₹251 Cr₹254 Cr₹323 Cr₹417 Cr₹425 Cr₹595 Cr₹750 Cr₹808 Cr
Equity₹553 Cr₹649 Cr₹905 Cr₹1,223 Cr₹1,765 Cr₹2,086 Cr₹2,489 Cr₹3,053 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹54 Cr₹258 Cr₹227 Cr₹172 Cr₹300 Cr₹353 Cr₹333 Cr₹598 Cr
Investing₹-13 Cr₹-60 Cr₹-45 Cr₹-84 Cr₹-259 Cr₹-141 Cr₹-49 Cr₹-248 Cr
Financing₹-21 Cr₹-114 Cr₹-15 Cr₹80 Cr₹198 Cr₹-69 Cr₹-65 Cr₹-71 Cr
Free Cash Flow₹54 Cr₹258 Cr₹227 Cr₹172 Cr₹300 Cr₹353 Cr₹333 Cr₹598 Cr
Shareholding
Promoter 43.87% Institutions 23.66% Public 32.47%
Efficiency & Working Capital
ROCE17.4%
Interest Coverage24.2
Dividend Payout—
Debtor Days80 d
Inventory Days120 d
Payable Days42 d
Cash Conversion Cycle158 d
Working Capital Days200 d
Shareholding Details

As of 2026-06-30

Promoter43.9%
FII17.5%
DII6.2%
Institutions23.7%
Public32.5%
Promoter Pledge0%
No. of Shareholders2,46,635
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters43.8%43.8%43.8%43.9%43.9%43.9%43.9%43.9%43.9%43.9%43.9%43.9%
FIIs15.1%15.6%15.6%18.6%21.3%22%22.2%19.9%16.9%8.1%16.8%17.5%
DIIs3.1%3.8%5.2%3.7%4.1%4.3%4.6%5.5%5.3%5.9%6.6%6.2%
Public37.9%36.8%35.4%33.8%30.7%29.9%29.4%30.7%33.9%42.1%32.8%32.5%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders2,07,9372,37,3772,54,6992,35,5002,48,8452,59,8132,57,2732,56,2212,65,7882,55,1532,46,2792,46,635
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Mark SaldanhaShareholding of Promoter and Promoter Group43.8%19.85 Cr
Orbimed Asia Iv Mauritius Fvci LimitedPublic Shareholding8.6%3.91 Cr
Uti-healthcare FundPublic Shareholding2.1%95,61,028
Kotak Mahindra Trustee Co Ltd A/c Kotak Special Opportunities FundPublic Shareholding1.1%51,47,937
Sandra SaldanhaShareholding of Promoter and Promoter Group0.1%3,30,456
Board of Directors
NameDesignationYear
Mark SaldanhaCMD & Executive Director2026
Sandra SaldanhaWhole Time Executive Director2026
Varddhman Vikramaditya JainNon Independent Executive Director / WTD2026
Digant Mahesh ParikhIndependent Non Exe. Director2026
Abhinna Sundar MohantyIndependent Non Exe. Director2026
Sunny SharmaNon-Exec & Non-Independent Dir2026
Shailaja VardhanIndependent Non Exe. Director2026
Srinivas MishraIndependent Non Exe. Director2026
HARSHAVARDHAN PANIGRAHICompany Sec. & Compli. Officer2026
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr—
Segments — Geography
RegionRevenueShare
US & North America₹922 Cr68.7%
Europe and UK₹261 Cr19.4%
Australia and New Zealand₹77 Cr5.8%
Local₹0 Cr0%
Rest of World₹82 Cr6.1%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹1554545
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-20Dividend (0.9/- per share)Final
dividend2026-08-20₹0.9 (90%)Final
forthcoming2026-08-20Dividend—
forthcoming2026-08-12Board Meetings—
dividend2025-08-01₹0.8 (80%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20262,242001702,260
2026200002
2026996001701,014
Insider / Designated-Person Trades

9 recent disclosure(s)

Sandra SaldanhaAcquisition · 63,276
Sandra SaldanhaAcquisition · 47,000
Arvind SinghDisposal · 2,000
Arvind SinghDisposal · 3,000
Arvind SinghDisposal · 6,500
Arvind SinghAcquisition · 3,000
Substantial Acquisitions (SAST)

1 disclosure(s)

Market11/06/2025 · 1,02,73,443
Company Information
Incorporated1992
ChairmanMark Saldanha
AuditorMSKA & Associates LLP
Investor Email[email protected] ; info@marksan
🌐 www.marksanspharma.com ↗

📍 11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Marc Technocrats LimitedMarco Cable & Conductor LimitedMarico LimitedMarine Electricals (India) Ltd.Marinetrans India LimitedMarkolines Pavement Technologies Ltd.Marsons LimitedMarushika Technology Ltd.Maruti Suzuki India Ltd.MAS Financial Services Ltd.Mask Investments LimitedMason Infratech LimitedAll “M” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search